Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for 'Click Chemistry'
HUNTSVILLE, Ala., April 17, 2013 /PRNewswire/ -- Serina Therapeutics, Inc., a pharmaceutical research and development company that has developed a proprietary, patented polymer technology for drug development, announced today that the company has entered into a worldwide exclusive license agreement with The Scripps Research Institute for "click chemistry" – a facile method of attaching molecules together in a precise and quantitative manner. Further details of the agreement and the financial terms were not disclosed.
"Click chemistry represents a major advance in how small molecules can be 'clicked' together," said Dr. Mike Bentley, Chief Scientific Officer of Serina Therapeutics. "This license agreement allows us to attach small molecules to POZ polymers in a precise, quantitative and reproducible manner, and that is critical to our drug development efforts."
Click chemistry was invented by Professor Barry Sharpless at The Scripps Research Institute. Dr. Sharpless shared the Nobel Prize in Chemistry in 2001 for his groundbreaking work in unraveling chiral catalysts.
Serina Therapeutics is a privately held pharmaceutical company located at the Hudson-Alpha Institute for Biotechnology in Huntsville, AL that develops novel polymer therapeutics based on its proprietary polyoxazoline (POZ) technology platforms. The founders and managers of Serina were formerly the key principals of Shearwater Polymers, a company that enabled twelve approved polyethylene glycol (PEG) products for various pharmaceutical partners. Besides developing its own pipeline of pharmaceutical products for Parkinson's disease and cancer, Serina is also partnering its technology with pharmaceutical companies to develop high value products addressing unmet clinical needs.
For more information on Serina Therapeutics, please visit their website at http://www.serinatherapeutics.com
About Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
SOURCE Serina Therapeutics, Inc.